Head & Neck Cancer News | Throat & Mouth Cancer Articles

Head and Neck Cancer News

HEAD AND NECK CANCER ADVISOR

Head and Neck Cancer News

FDA_drug approval

Keytruda Approved for First Line Treatment of Unresectable, Recurrent HNSCC

The FDA has approved Keytruda (pembrolizumab; Merck) for first line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression.